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Outcome and reproducibility of Heart Team decisions: a single center experience
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Background: A multidisciplinary team (MDT) approach is now a class IC recom-
mendation in the European and American guidelines for decision-making in patients
with complex coronary artery disease (CAD). The Heart Team (HT) consists of at
least one interventional cardiologist, a cardiac surgeon and a non-invasive cardiolo-
gist. The aim of this study was to evaluate the implementation and consistency of HT
decisions in a tertiary cardiac centre.
Methods: We prospectively evaluated our data derived from 51 MDT meetings held
between April 2012 and April 2013. A subset of cases was randomly selected and re-
presented with the same clinical data, at least 6 months after the initial decision in
order to evaluate the consistency of initial decisions.
Results: Amongst patients discussed (n¼399) 23% were females. An average of 8
patients were discussed in each weekly meeting. This was attended by a median
number of 1 non-interventional cardiologist, 3 interventional cardiologists and 3 car-
diac surgeons. The most common HT decisions included continued medical man-
agement (30%), coronary artery bypass grafting (CABG) (26%) and percutaneous
coronary intervention (PCI) (17%). Other decisions, such as further assessment of
symptoms or evaluation with dobutamine stress echo, cardiac MRI, repeat coronary
angiogram, pressure wire studies (PWS), intravascular ultrasound (IVUS) or exercise
treadmill test (ETT) were made in 27% of the cases discussed. HT decisions were
implemented in 93% of the cases. The most common reasons for non-implementation
were unrecognised comorbidities (n¼11), change of symptoms (n¼7), patient refusal
(n¼7) and death (n¼4). On re-discussion of the same data (n¼25) within a median
period of 9 months 20% of decisions (n¼5) differed from the original HT
recommendation.
Conclusions: The Heart Team is a robust process in the management of patient with
complex CAD and decisions are largely reproducible. Although outcomes are
successfully implemented in the majority of the cases, it is important that all clinical
information is available during discussion and patients' preference is taken into
account.
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Background: Percutaneuse coronary interventions have increased in recent years in
high risk patients. The goal of this study was to evaluate this trend in type 2 diabetes
(DM) patients undergoing PCI in the United States.
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate
the age-adjusted incident rate of PCI performed in type 2 DM patient from 1988 to
2006 in the United State using ICD-9 coding for PCI and type 2 DM.
Results: A total population of 504371 type 2 DM patients underwent PCI between
1988-2006 were available for our study over the age of 40. We found that age adjusted
rate of PCI performed in type 2 DM patient gradually increased with highest rate
in 2006. Age adjusted rate for DM patients undergoing PCI was 10.1 per 100,000 in
1988 vs. 70.1 per 100.000 in 2006 (p<0.01). Non-DM patient had similar increase in
PCI over the years studied.
Conclusions: PCI performed increasingly in type 2 DM patients in last few decades.
The cause of this trend is not known but is most likely related to PCI being performed
more frequently in high risk patient or related to increasing incidence of PCI in the
popolation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-316
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Background: The effect of glycemic control on major cardiovascular (CV) and
cerebrovascular events (MACCE) after percutaneous coronary intervention in patients
with Type 2 diabetes (DM) remains controversial.
Methods: We report an international, observational study on DM patients with
coronary artery disease eligible for percutaneous coronary intervention. Patients with
Type 1 diabetes and ST elevation myocardial infarction (MI) were not included.
Clinical follow up and glycemic control as assessed by glycosylated hemoglobin
(HbA1c) were obtained at 1 year.
Results: A total of 1,036 patients aged 61.9 (+/-0.3) years were included. CV risk
factors included smoking, hypercholesterolemia, hypertension and overweight in
49.7%, 78.2%, 76.6% and 47.6%, respectively. Clinical presentation included acute
coronary syndrome, silent ischemia and stable angina in 22%, 15.6% and 30.8%,
respectively. 1,687 coronary stenosis were treated with at least one Xience everolimus
eluting stent (EES) in the the left main (n¼52), the left anterior descending artery
(n¼744), the left circumﬂex artery (n¼506) or the right coronary artery (n¼538). The
mean length and diameter of the implanted EES were 19.0+/-0.2mm and 2.88+/-
0.01mm, respectively. MACCE was observed in 95 (9.2%) patients: CV death (n¼16
(1.5%)), myocardial infarction (n¼8 (0.8%)), ischemia driven revascularization (66
(6.4%)) and ischemic stroke (n¼5 (0.5%)). The MACCE rate was not signiﬁcantly
different among the low, intermediate and high tertile groups of HBA1c.
Conclusions: The use of EES in a large population of DM2 patients is associated with
a low MACCE rate at 1 year. No beneﬁcial effect of good glycemic control as
assessed by HBA1c on MACCE was observed in this “all-comer” diabetic population
at 1 year.
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Background: Mechanisms for cardioprotection with Glucagon-like Peptide-1 (GLP-
1) are unclear. Human studies have mainly assessed the effects of GLP-1 when
administered after an ischemic insult, when reperfusion injury pathways have been
activated. There is however, limited data investigating the impact of GLP-1 on supply
ischemia when given before PCI.
Methods: 30 patients with normal LV function were studied during elective LAD
PCI. Pressure-volume loops were recorded using a LV conductance catheter at
baseline, during 1-min low-pressure balloon occlusion (BO1), after 30mins recovery,
and during a 2nd 1-min balloon occlusion (BO2). Patients were randomized to receive
either IV saline (control) or GLP-1 (7-36; 1.2 pmol/kg/min) given before BO1.
Coronary wedge pressure (Pw) & simultaneous coronary artery/sinus glucose samples
were measured during BO1. Data were analyzed ofﬂine by a blinded reviewer for
measures of systolic (dP/dTmax) & diastolic (dP/dTmin) function.
Results: Compared with controls, pre-treatment with GLP-1 reduced LV dysfunction
during BO1 (D dP/dTmax -5.7% vs -15.3%, p¼0.04; D dP/dTmin -10.4% vs -21.8%,
p¼0.04), improved recovery at 30mins (D dP/dTmax +4.8% vs -12.2%, p¼0.03) &
reduced LV dysfunction after BO2 (D dP/dTmax -7.7% vs -25.3%, p¼0.02; D dP/
dTmin -15.3% vs -30.3%, p¼0.05). Collateral recruitment (Pw 24.4 vs 20.3mmHg,
p¼0.36; pressure-derived collateral ﬂow index 0.19 vs 0.17, p¼0.57) & glucose
utilisation was similar in both groups.acts/POSTER/Miscellaneous Coronary Topics B101
